Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Candida spp.
Five clinical trials of the efficacy of amphotericin B colloidal dispersion (ABCD) primarily in patients unable to tolerate or failing treatment with conventional amphotericin B (CAB) were reviewed. A total of 572 patients were treated. Systemic candidal infections were identified in 107 evaluable patients and 239 in the intent-to-treat population. Seventy percent of the evaluable patients and 50% of the intent-to-treat patients achieved a complete or partial response. There were no significant differences either in response rates for different underlying causes or in response rates according to enrollment reason. The efficacy of ABCD at doses of 3-4 mg/kg/ day in disseminated candidiasis appears to be similar to that in studies using CAB. Renal and hepatic toxicity of ABCD is low.
Dupont
B
B
Institut Pasteur, Paris, France.
D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002177:Candidiasis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D016469:Fungemia / Q000188:drug therapy*; D006801:Humans; D015337:Multicenter Studies as Topic; D016896:Treatment Outcome
D000935:Antifungal Agents; D000666:Amphotericin B